ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Ginsenoside Rh2 inhibits non-small-cell lung cancer malignant progression through targeting AURKA.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Non-small-cell lung cancer (NSCLC) is one of the most common and deadly malignant tumors worldwide. Treatment still faces challenges, including drug resistance and a complex tumor microenvironment. The natural product ginsenoside Rh2 (G-Rh2) has antitumor potential with multiple targets and low toxicity. However, its specific molecular mechanisms in NSCLC remain unclear. The study integrated transcriptomics analysis (Gene Expression Omnibus (GEO) dataset GSE18842) with drug target prediction (SwissTargetPrediction) to identify common targets between G-Rh2 and NSCLC. Core targets were identified through protein-protein interaction (PPI) network analysis. Gene and protein expression was determined through real-time quantitative PCR (RT-qPCR) and Western blot. The mechanism of G-Rh2 and its association with AURKA were validated using molecular docking, in vitro cellular assays (colony formation, apoptosis, migration, glycolysis level detection, and macrophage co-culture), and in vivo nude mouse xenograft models. AURKA was identified as a core target of G-Rh2 against NSCLC. Its expression was significantly elevated in NSCLC tissues and cell lines, and was related to poor overall survival. G-Rh2 inhibited cell colony formation and migration while inducing apoptosis, downregulated hypoxia-inducible factor-1α (HIF-1α) expression, and reduced glucose consumption, lactate production, and adenosine triphosphate (ATP) levels, but these effects were reversed by Aurora kinase A (AURKA) overexpression. Besides, AURKA upregulation weakened the promotion of G-Rh2 on macrophage M1 polarization and the inhibition on M2 polarization. More importantly, G-Rh2 enhanced cisplatin (DDP) chemotherapy sensitivity both in vivo and in vitro, whereas AURKA overexpression reversed these effects. G-Rh2 regulates malignant progression in NSCLC by targeting AURKA. It inhibits proliferation and migration, induces apoptosis, reshapes the metabolic and immune microenvironment, and sensitizes chemotherapy. AURKA serves as a potential biomarker and combination therapy target for NSCLC treatment.
Indexed as
Identifiers
42142138What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.